Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
出版年份 2021 全文链接
标题
Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
作者
关键词
-
出版物
Cancers
Volume 13, Issue 15, Pages 3800
出版商
MDPI AG
发表日期
2021-07-28
DOI
10.3390/cancers13153800
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early antibody response in healthcare professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)
- (2021) Julien Favresse et al. CLINICAL MICROBIOLOGY AND INFECTION
- Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution
- (2021) Fulvia Pimpinelli et al. Journal of Hematology & Oncology
- Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
- (2021) Sarah Bird et al. Lancet Haematology
- Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
- (2021) Dami A. Collier et al. NATURE
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
- (2020) Ajai Chari et al. BLOOD
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- (2019) Ujjawal H. Gandhi et al. LEUKEMIA
- The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa
- (2019) Laura Moreno et al. CLINICAL CANCER RESEARCH
- Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients
- (2019) Kristine A. Frerichs et al. HAEMATOLOGICA
- CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
- (2018) Limo Chen et al. Cancer Discovery
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- The T Cell in Myeloma
- (2016) Douglas Joshua et al. Clinical Lymphoma Myeloma & Leukemia
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Guidelines for determination of the number of prior lines of therapy in multiple myeloma
- (2015) S. V. Rajkumar et al. BLOOD
- Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
- (2014) C. Blimark et al. HAEMATOLOGICA
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- CD19+CD24hiCD38hi B Cells Maintain Regulatory T Cells While Limiting TH1 and TH17 Differentiation
- (2013) F. Flores-Borja et al. Science Translational Medicine
- New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
- (2012) Giovanni Palladini et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More